Alexander Monro Hospital

What Alexander Monro Hospital does

Alexander Monro Ziekenhuis (AMZ), founded in April 2013 in Bilthoven, Netherlands, is the first and only hospital in the country dedicated exclusively to breast cancer and breast conditions. It operates a second location, 'Alexander Monro regio Zuidoost', opened in 2020 within SJG Weert hospital to extend geographic reach into the southeastern Netherlands. The hospital delivers a comprehensive care pathway covering diagnostics (mammography, MRI, CT, PET, ultrasound, stereotactic biopsy, DEXA), surgical oncology (breast-conserving surgery, mastectomy, MARI procedure, axillary dissection, prophylactic surgery), oncoplastic and reconstructive plastic surgery, systemic treatments (chemotherapy, hormone therapy, targeted therapy, immunotherapy), radiotherapy coordination (including proton therapy), hereditary risk assessment for BRCA1/2 and CHEK2 mutations, second opinion services, and supportive care (AYA, palliative, menopause, lifestyle). All services are coordinated through daily multidisciplinary team meetings, and mammacare nurses are reachable 24/7 by phone.

Technology infrastructure centers on two Siemens Healthineers MAMMOMAT B.brilliant mammography systems installed in November 2024 with 50° Wide-Angle tomosynthesis and AI co-assessment in diagnostics, complemented by MRI, ultrasound, CT, PET, and DEXA imaging modalities. The hospital holds ISO9001 and NEN8009 certification (June 2025), is a member of the NVZ branch association (January 2025), participates in the NABON Breast Cancer Audit, and meets SONCOS guidelines for oncology. Revenue is generated through reimbursement from all Dutch health insurers (zorgverzekeraars) under the standard Dutch healthcare financing model, with coverage confirmed through 2026. Patients access care nationally through GP (huisarts) referrals, population screening follow-ups, self-referral, and second opinion requests. The 'Ken je borsten' (Know Your Breasts) national awareness campaign, co-run with the Stichting Breast Care Foundation, extends AMZ's public health and brand footprint across the Dutch market.

Name

Alexander Monro Hospital

Legal name

Alexander Monro Ziekenhuis

Website

https://alexandermonro.nl

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Short description

Alexander Monro Hospital is the first and only Dutch hospital exclusively dedicated to breast cancer and breast conditions. Operating from Bilthoven and Weert, it provides end-to-end breast diagnostics, surgery, and systemic therapy reimbursed by all Dutch health insurers.

Ownership category

akta.pro rank

Product category

Specialized Breast Cancer Hospital Services

NAICS

General Medical and Surgical Hospitals (622110), Offices of Physicians (except Mental Health Specialists) (621111)

SIC

Services-Hospitals (8060)

akta.pro primary industry

Breast Oncology (HLAKAFAJ)

akta.pro secondary industries

Women’s Imaging & Breast Health Centers (HLAFAJAJ), Breast Imaging Centers (Mammography/Tomosynthesis) (HLAFAKAD)

Keywords

• Breast cancer hospital
• Oncology diagnostic imaging
• Mammography screening
• Surgical oncology services
• Second opinion services

Headquarters

HQ city

Bilthoven

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others

Revenue model

1. Insured Healthcare Services: As a Dutch hospital, Alexander Monro generates revenue through reimbursement from Dutch health insurers (zorgverzekeraars). All care provided — diagnostics, treatments, surgeries, and second opinions — is covered by all Dutch health insurance companies, confirmed for 2026 as well. This is the standard Dutch healthcare financing model where insurers reimburse providers for insured medical care.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

Alexander Monro Hospital (Alexander Monro Ziekenhuis) is the Netherlands' first and only hospital entirely dedicated to the diagnosis and treatment of breast cancer and breast conditions. It delivers the full care pathway — diagnostic imaging (MAMMOMAT B.brilliant tomosynthesis, MRI, CT, PET, ultrasound, biopsy), oncological and reconstructive surgery, radiotherapy, chemotherapy, hormone, targeted and immunotherapy, genetic testing, second opinions, and supportive care — coordinated through daily multidisciplinary team meetings and reimbursed by all Dutch health insurers.

Product overview

Alexander Monro Hospital is a specialized breast cancer and breast condition hospital offering comprehensive diagnostic and treatment services through a unified hospital system. The core offering includes advanced mammography diagnostics (MAMMOMAT B.brilliant with AI-assisted review), radiological imaging (MRI, CT, PET, ultrasound), surgical interventions (breast-conserving surgery, mastectomy, reconstructive surgery), and systemic treatments (chemotherapy, hormone therapy, immunotherapy, targeted therapy). The hospital operates specialized clinics for high-risk patients and genetic carriers, provides second opinion consultations, and offers pre/post-treatment care including AYA care and palliative services. A digital patient portal and healthcare provider portal support patient access. The 'Ken je Borsten' awareness campaign extends public health education. All services are coordinated through daily multidisciplinary team meetings, with 24/7 care availability.

Differentiator

Problem solved

Functional benefit

Brands

• Alexander Monro regio Zuidoost: Regional location of the specialized breast cancer hospital operating in partnership with SJG Weert

Products and services

• Diagnose & Onderzoek (Breast Imaging & Diagnostics Program) Integrated breast diagnostic service covering mammography (with tomosynthesis), MRI, ultrasound, CT, PET, DEXA, and stereotactic biopsy for women and men presenting with breast symptoms, abnormal screening results, or dense breast tissue. Intended for patients referred by their GP, recalled from the national population screening, or self-referring for evaluation.
• Mammografie (MAMMOMAT B.brilliant Vrouwvriendelijke Mammografie) Advanced digital mammography service using the Siemens Healthineers MAMMOMAT B.brilliant system with 50° Wide-Angle tomosynthesis for high-resolution 3D breast imaging in approximately 5 seconds per scan, paired with woman-friendly (vrouwvriendelijke) exam design to reduce discomfort. Indicated for routine screening, screening follow-up, symptomatic evaluation, and dense-breast assessment.
• AI-Medebeoordeling in Mammografie Diagnostiek (AI-Assisted Mammography Diagnosis) Computer-vision AI co-assessment integrated into the mammography workflow to support breast radiologists in lesion detection and characterization, improving diagnostic accuracy and reducing reading time. Available as part of the diagnostic pathway for patients undergoing mammography at AMZ.
• Chirurgie en Oncologische Chirurgie (Breast Surgical Oncology) Surgical oncology service for breast cancer covering breast-conserving surgery, mastectomy (with immediate reconstruction where indicated), the MARI procedure for axillary staging, axillary lymph node dissection, and prophylactic (risk-reducing) surgery. Targeted at confirmed breast cancer patients and high-risk genetic carriers requiring risk-reducing mastectomy.
• Plastische Chirurgie (Oncoplastic & Reconstructive Breast Surgery) Oncoplastic and reconstructive plastic surgery delivered in coordination with oncological surgeons, offering immediate reconstruction after mastectomy and other breast reconstruction procedures. Targeted at breast cancer patients undergoing surgical treatment as well as risk-reducing surgery candidates.
• Radiotherapie (Radiation Therapy including Proton Therapy) Radiation oncology service coordinated by AMZ radiation oncologist Dr. Felderhof, with treatment delivered at partner radiotherapy centers including UMC Utrecht. Covers standard radiotherapy and proton therapy. Indicated for breast cancer patients as part of breast-conserving or post-mastectomy treatment plans.
• Chemotherapie (Chemotherapy Day Treatment) Systemic chemotherapy delivered in AMZ day-treatment facilities, including neo-adjuvant and adjuvant regimens for breast cancer. Targeted at breast cancer patients requiring systemic cytotoxic treatment as part of their multidisciplinary plan.
• Hormoontherapie (Hormone Therapy) Endocrine / hormone therapy using agents such as Tamoxifen and aromatase inhibitors for hormone-receptor-positive breast cancer. Targeted at patients with hormone-sensitive tumors as part of long-term adjuvant or metastatic treatment.
• Immunotherapie (Cancer Immunotherapy) Immunotherapy regimens that engage the patient's immune system against breast cancer cells. Indicated for selected breast cancer subtypes based on multidisciplinary review.
• Doelgerichte Therapie (Targeted Therapy) Targeted therapy using drugs that act on specific molecular mechanisms (e.g., HER2-targeted agents) in breast cancer. Indicated for patients with appropriate tumor biomarkers as determined by the multidisciplinary team.
• Erfelijkheidsonderzoek (Genetic Testing & Counseling) Hereditary cancer risk assessment and genetic testing for mutations including BRCA1, BRCA2, and CHEK2, with counseling delivered in collaboration with UMC Utrecht's Dr. Margreet Ausems. Indicated for individuals with personal or family history suggesting hereditary breast cancer risk.
• Second Opinion Service Expert re-evaluation of breast cancer diagnosis and treatment plans by AMZ specialists for patients seeking confirmation or alternative perspectives on care proposed at other hospitals. Marketed as 'Expert in second opinions' and reimbursed under the standard Dutch healthcare insurance model.
• Verhoogd Risico en Gendragers Polikliniek (High-Risk & Genetic Carrier Clinic) Specialized surveillance program for individuals with hereditary predisposition (BRCA1/2, CHEK2, etc.) or familial increased breast cancer risk, providing annual MRI/mammography monitoring, risk assessment, and counseling on prophylactic options. Targeted at known genetic carriers and individuals with significantly elevated breast cancer risk.
• AYA-zorg (Adolescent & Young Adult Oncology Support) AYA (Adolescents and Young Adults, typically ages 18-35) oncology care addressing the medical, psychosocial, and survivorship needs of younger breast cancer patients. Targeted at younger patients navigating breast cancer alongside education, career, or family planning.
• Palliatieve Zorg (Palliative Care) Palliative care focused on quality of life, symptom control, and psychosocial support for patients with advanced or metastatic breast cancer. Targeted at patients with incurable disease requiring comfort-oriented and supportive care.
• Voorzorg en Nazorg (Pre-Treatment & Aftercare / Survivorship Program) Pre-treatment counseling and post-treatment supportive services including integral care, lifestyle and nutrition counseling, rehabilitation programs, osteoporosis management, menopause support, and psychological care across the treatment and survivorship journey. Targeted at breast cancer patients before, during, and after active treatment.
• Patientenportaal — Mijn Alexander Monro (Patient Portal) Online patient portal at mijn.alexandermonro.nl (DigiD-authenticated) enabling patients to access medical records, schedule and manage appointments, and communicate with AMZ care teams. Available to all AMZ patients as part of the hospital's digital care offering.
• Zorgverlenersportaal (Healthcare Provider Portal) Online portal for referring GPs and other healthcare providers (ZorgID-authenticated) to submit referrals, review protocols, share first-line diagnostic results, and access training/education (nascholingen) and AMZ referrer campaigns. Targeted at Dutch GPs, screening radiologists, and other referring clinicians.
• Multidisciplinair Overleg (MDO) — Daily Multidisciplinary Team Consultation Daily co-located multidisciplinary team (MDO) meeting in which oncological and plastic surgeons, medical and radiation oncologists, breast radiologists, pathologists, and mammacare nurses collectively review cases and decide on diagnosis and treatment plans, enabling rapid decision-making through specialist consensus. Available to all AMZ patients as part of the standard care pathway.

Quantifiable outcome

• Patients with low-stage breast cancer at AMZ show more favorable prognosis compared to the Dutch average (IKNL data)
• +2 more outcomes

Named customers3 records

Segments7 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• UMC UtrechtcoreStrategic or Co-development Partner · 1 January 2020Intensive collaboration on academic medical care, science, innovation, radiotherapy, and pathological diagnostics. The UMC Utrecht's Department of Pathology performs all tissue diagnostics for AMZ. AMZ also collaborates with UMCU for supplementary lab and microbiology testing. Dr. Margreet Ausems (clinical geneticist from UMCU) runs hereditary cancer consultations at AMZ. Patients from the central Netherlands region are treated for radiotherapy by AMZ's radiation oncologist at UMC Utrecht directly.
• SJG WeertminorStrategic or Co-development Partner · 1 January 2020Second Alexander Monro location opened in 2020 as 'Alexander Monro regio Zuidoost' within the SJG Weert hospital. Extends AMZ's specialized breast cancer services to the southeastern region of the Netherlands, improving geographic accessibility for patients in that area.
• Siemens HealthineerscoreTechnology or IntegrationOver 10-year partnership for state-of-the-art mammography technology. AMZ installed two MAMMOMAT B.brilliant systems — the most advanced mammography platform currently available — featuring 50° Wide-Angle tomosynthesis for superior diagnostic accuracy. Contract signed by bestuurder Marjolein de Jong and Siemens Healthineers' algemeen directeur Paul Riswick. The partnership enables the most accurate and rapid breast cancer diagnosis through cutting-edge imaging technology.
• Stichting Breast Care Foundation (BCF)coreStrategic or Co-development PartnerJoint operation of the national 'Ken je borsten' (Know Your Breasts) public awareness campaign, co-founded by AMZ bestuurder Marjolein de Jong. The campaign aims to reach all women and men in the Netherlands to increase awareness of the 12 most common breast cancer symptoms and the importance of early detection. BCF also accepts donations to support breast health awareness and research.
• Radiotherapy Centers (regional)minorChannel Partner/ Reseller/ DistributorAMZ arranges radiotherapy treatment at nearby centers for patients whose treatment plans require radiation therapy. The AMZ radiation oncologist (Dr. Felderhof) discusses options with patients and ensures seamless coordination. Patients from the central Netherlands region are typically treated at UMC Utrecht.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Regional players

• Institut Curie: France's historic specialty center for breast cancer research and treatment. Operates as a dedicated cancer hospital-research center hybrid with strong breast cancer focus, making it the international benchmark for the single-disease cancer hospital model AMZ embodies.
• Karolinska Comprehensive Cancer Centre: Sweden's dedicated oncology center within the academic hospital system. Compares as a publicly reimbursed European specialty oncology provider organized around multidisciplinary cancer care.
• Institut Jules Bordet: Belgium's dedicated oncology hospital and research center, part of the HUB (Hôpitaux Universitaires de Bruxelles). Comparable as a single-disease specialty hospital operating in a neighboring country's similar reimbursement environment.

Broad incumbents

• MD Anderson Cancer Center: The global benchmark for dedicated, single-focus cancer hospitals. Operates as a comprehensive specialty oncology center with full multidisciplinary teams, research, and brand-leading patient volumes — a scaled-up structural analogue to AMZ.
• Gustave Roussy: Europe's largest dedicated comprehensive cancer center treating all cancer types with multidisciplinary specialty teams. Comparable in operating as a specialty oncology hospital at scale, though broader in scope than AMZ.
• Memorial Sloan Kettering Cancer Center: U.S. specialty cancer hospital and research institution with strong breast cancer program. Demonstrates the global scalability ceiling for dedicated single-disease cancer hospital brands.
• Dana-Farber Cancer Institute: U.S. specialty cancer hospital affiliated with Harvard focused exclusively on adult and pediatric oncology. Comparable in operating as a dedicated cancer hospital with multidisciplinary breast oncology programs.
• Erasmus MC Cancer Institute: Dutch academic hospital with a comprehensive cancer center treating breast cancer among other oncology. Competes for the same IKNL-tracked patient population and operates as a broader specialty referral option versus AMZ's exclusive focus.

Direct peers

• Princess Máxima Center for Pediatric Oncology: The Netherlands' other single-disease specialty hospital — exclusively focused on pediatric oncology, similar to AMZ's exclusive focus on breast cancer. Operates as a centralized national referral center with full multidisciplinary care, research, and family support, making it the closest structural peer in country.
• Netherlands Cancer Institute (NKI / Antoni van Leeuwenhoek): The Netherlands' leading dedicated oncology hospital and research institute, combining specialized cancer care with academic research. Comparable in providing oncology specialty services nationally with multidisciplinary care, and the most direct competitor for breast cancer patients seeking specialist treatment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MonroZiekenhuis
• YouTubeyoutube.com/channel/UCzQvSQsWsLP6tT3xk9L7W_Q
• LinkedInlinkedin.com/company/alexander-monro-borstkankerziekenhuis
• Facebookfacebook.com/MonroZiekenhuis

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alexander Monro Hospital